Last updated: July 28, 2026
Ultravist 150 clinical trials update and market projections: current evidence, competitive landscape, and exclusivity risk
Ultravist 150 (iopromide 300 mg iodine/mL; iodinated contrast media for CT and angiography) has limited visible “active” clinical-trial disclosure tied to new Ultravist-branded development because the product is an established small-molecule contrast agent with generic and authorization pathways already in place across most major markets. Practical near-term R&D and commercial risk concentrates on (1) formulation and manufacturing changes, (2) brand-level contracting and tender dynamics, and (3) patent and data exclusivity status in each jurisdiction rather than new clinical efficacy trials.
Because “Ultravist 150” is a branded presentation within the iopromide portfolio, market access and competitive pressure primarily follow pricing, distribution, and regulatory listing status, not new clinical outcomes.
What clinical trials updates exist for Ultravist 150 (iopromide 300 mg I/mL) in 2024–2026?
No complete, verifiable set of recent, sponsor-attributed interventional trials for “Ultravist 150” specifically is available in the public record needed for a precise update (study identifiers, enrollment, endpoints, timelines, results). What is typically visible for established iodinated contrast agents is:
Where new evidence usually appears
- Comparative imaging performance studies (non-inferiority) of iodinated contrast agents, often using iopromide arms.
- Safety registries or observational cohorts for contrast-associated acute kidney injury and hypersensitivity.
- Protocol comparisons (injection rate, dilution, patient preparation, imaging timing).
- Device-administration studies (power injector parameters).
How to treat “trial updates” for an established contrast agent
For a marketed, off-patent contrast medium, the clinical trial signal that matters for business planning is usually not new FDA-label expansion but rather:
- label maintenance,
- risk-management updates (hypersensitivity, renal impairment precautions),
- and comparative value arguments used in procurement.
Featured snippet answer
Ultravist 150 clinical-trial “updates” in the sense of new interventional efficacy programs are not the main driver of near-term strategy; market outcomes are driven by regulatory listing, procurement pricing, and safety-management positioning rather than new outcomes trials.
Ultravist 150 market size: how big is iopromide 300 and where does Ultravist 150 fit?
Market structure
Ultravist 150 is positioned within the broader iodinated contrast media market, where:
- iopromide (including 300 mg I/mL presentations) competes with non-ionic monomers and other iodinated agents used for CT, angiography, and related imaging.
- procurement is often national or hospital-group tender-based, with product switching supported by comparable imaging indications and safety profiles.
Business-relevant market segments
- CT (adult and pediatric where applicable)
- Angiography (hospital specialty workflows)
- Emergency departments (high-volume acute imaging)
- Cardiology imaging services (depending on local tender controls)
Featured snippet answer
Ultravist 150 is a brand within the iopromide 300 mg I/mL segment of the iodinated contrast media market, where commercial performance is primarily tender- and price-driven, with differentiation tied to supply reliability, contract terms, and administration convenience.
What is the competitive landscape for Ultravist 150 (iopromide) vs Omnipaque and other CT contrast brands?
Key competitive categories
- Iodixanol (often branded as Visipaque in some markets)
- Iohexol (Omnipaque in many regions)
- Ioversol and other non-ionic iodinated agents
- Generic iopromide presentations where authorized
How brands compete in practice
- Shelf availability and lead-time reliability
- Tender pricing and rebate structures
- Supply capacity and pack formats (vial sizes, bottle/packaging)
- Device compatibility for power injectors
- Pharmacovigilance and risk-management documentation
Competitive implication for Ultravist 150
Unless a brand holds distinct IP on specific concentrations, dosing regimens, or packaging/manufacturing, differentiation tends to compress over time as authorized generics expand.
What patents protect Ultravist 150 and how strong is the IP estate?
Ultravist 150 is iopromide-based and typically sits within an IP landscape where:
- the original active-substance IP is long expired,
- remaining protection (if any) is concentrated in formulation, packaging, manufacturing, and regulatory exclusivity tied to specific submissions in a given country.
A precise “patent estate” mapping (patent numbers, priority dates, assignees, expiration dates, family members) cannot be produced from the information available here because no jurisdiction-specific Orange Book, national register, or litigation docket content is included in the prompt.
Featured snippet answer
For an established branded iopromide contrast agent, IP protection, where present, is usually limited to jurisdiction-specific formulation/manufacturing and associated regulatory exclusivity rather than compound-level patents.
When does Ultravist 150 lose exclusivity, and what generic entry risks exist?
A jurisdiction-accurate answer requires Orange Book listings, exclusivity codes, and each regulator’s status for the exact concentration and presentation. Those inputs are not included in the prompt, so a complete exclusivity timeline by country is not possible in a way that would be actionable for legal or licensing decisions.
Practical entry-risk framing
For contrast media:
- generic competition often follows chemistry/manufacturing equivalence plus authorized labeling alignment,
- brand erosion is tied to contract cycles and switching barriers (availability, packaging, and local tender policies).
Featured snippet answer
Generic entry risk for iopromide-based contrast brands is most influenced by tender and authorized listing status in each country rather than by compound exclusivity cliffs.
What is the Orange Book status of Ultravist 150 in the US?
A complete Orange Book status requires the exact FDA application number(s), listed active ingredient (iopromide), dosage form, strength, and the specific listing records. None are provided here, so a correct Orange Book “listed drug” status and exclusivity/Orange Book patent term summary cannot be produced.
Featured snippet answer
Orange Book status and listed patents cannot be stated accurately without the specific FDA listing records for the Ultravist 150 presentation.
What patent litigation affects iopromide contrast media brands like Ultravist?
Litigation-impact assessment requires:
- docket searches (e.g., ANDA-related paragraph IV suits for equivalent iopromide presentations),
- settlement agreements and stipulations,
- and court outcomes affecting launch timing.
No litigation docket content is available in the prompt, so no specific litigation dates, case captions, or settlement terms can be cited.
Featured snippet answer
Patent litigation cannot be mapped for Ultravist 150 without jurisdiction-specific case identifiers and FDA listing linkages.
How does Ultravist 150 compare with alternative iodinated contrast agents for imaging safety and renal outcomes?
For iodinated contrast media broadly, comparative safety conclusions in the literature often show:
- low absolute rates of severe reactions,
- careful risk stratification for prior hypersensitivity and renal impairment,
- renal risk that is typically managed through hydration protocols, patient selection, and avoidance of nephrotoxic co-medications.
Business relevance:
- procurement and guideline adherence often hinge on safety-management protocols more than granular differences in endpoints.
- the “value argument” is often consistent across brands: comparable diagnostic performance with reliable administration and risk mitigation.
Featured snippet answer
Ultravist 150 competes on practical safety workflow and procurement terms; its differentiation versus other iodinated contrast agents is usually not driven by brand-new comparative outcome superiority.
How strong is Ultravist 150’s commercial positioning: pricing, contracts, and revenue outlook?
Revenue drivers
- Hospital tender cycles and contract renewals
- Competitive price erosion from authorized generics
- Supply chain stability
- Pack size and dosing convenience for high-volume imaging centers
Forecast mechanics for contrast media
A realistic projection model for an established contrast agent typically uses:
- unit demand linked to CT volume and angiography utilization,
- penetration changes caused by tender switching,
- average selling price (ASP) drift based on generic mix.
Featured snippet answer
Ultravist 150 revenue outlook is most sensitive to tender pricing and generic share shifts rather than to new clinical trial results.
Clinical, regulatory, and supply timeline: what should planners watch next for Ultravist 150?
Even without new efficacy trials, planners should monitor:
- regulatory label updates and risk wording changes (hypersensitivity precautions, renal impairment guidance)
- manufacturing site changes and batch release continuity
- distribution disruptions affecting tender fulfillment
- procurement policy changes in major hospital systems
Featured snippet answer
The next commercial inflection points for Ultravist 150 will come from regulatory maintenance actions and tender-driven switching dynamics.
Key Takeaways
- Ultravist 150 is an established iopromide 300 mg I/mL contrast agent; near-term strategy and business risk concentrate on market access, procurement pricing, and authorized listing dynamics rather than new pivotal clinical trials.
- Competitive pressure is primarily driven by alternative iodinated contrast brands and generic iopromide penetration.
- A precise exclusivity, Orange Book, and patent- or litigation-based exclusivity timeline requires jurisdiction-specific FDA listing and legal docket inputs not provided here.
- Commercial projections should be built on CT volume-linked demand, tender cycles, and ASP compression risk from authorized equivalents.
FAQs
- What are the main indications for Ultravist 150 in diagnostic imaging markets?
- How do hospitals typically decide between iopromide brands and competing non-ionic iodinated contrast agents?
- What risk-management measures are most relevant for iodinated contrast media hypersensitivity and renal impairment precautions?
- What manufacturing changes most often trigger regulatory review for established contrast agents like iopromide?
- How does tender timing usually affect when hospitals switch from branded iodinated contrast media to authorized generics?
References (APA)
- No sources are included because the prompt does not provide the required FDA/regulatory listing records, patent numbers, or specific clinical trial identifiers to cite accurately.
